In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML
Mutation-Agnostic Treatment Advances
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.